Novacyt SAS is a diagnostics company, which engages in the business of developing, producing, and selling vitro and molecular diagnostic tests and products for a wide range of infectious diseases. The company is headquartered in Velizy-Villacoublay, Ile-De-France and currently employs 234 full-time employees. The company went IPO on 2012-10-12. The firm develops and markets solutions dedicated to the field of liquid-based cytology and molecular biology. The company provides diagnostic products used in oncology, microbiology, haematology, and serology testing. The firm develops secure automated cytology named NovaPrep Processor System. The company offers a solution of cytological sampling to help in the detection of precancerous and cancerous lesions. The company creates bottles specifically dedicated to the optimization of cell collection. The Company’s range of products includes Bottle Gyn and No Gyn Bottle.
Follow-Up Questions
Novacyt SA のCEOは誰ですか？
Mr. Lyn Rees は Novacyt SA の Chief Executive Officer で、2023 から在籍しています。
NVYTF の株価パフォーマンスは？
NVYTF の現在の価格は $0 で、最終取引日から 0% decreased 変動しました。
Novacyt SA の主な事業テーマや業界は？
Novacyt SA は Biotechnology 業界、セクターは Health Care に属しています。
